Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 101–200 of 1,001
Emerging organoid models: leaping forward in cancer research
Fan, H., Demirci, U., & Chen, P. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0832-4 · Cited by 199
“Cancer organoids derived from patients’ biopsies displayed the 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value, compared to the drug responses in the corresponding patients [62].”
BackgroundResultSignaling in the stem cell niche: regulating cell fate, function and plasticity
Chacón-Martínez, C. A., Koester, J., & Wickström, S. A. (2018) · Development · doi:10.1242/dev.165399 · Cited by 198
Wang, H.-M., Zhang, C.-Y., Peng, K.-C., Chen, Z.-X., Su, J.-W., Li, Y.-F., Li, W.-F., Gao, Q.-Y., Zhang, S.-L., Chen, Y.-Q., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100911 · Cited by 192
Organoid models of gastrointestinal cancers in basic and translational research
Lau, H. C. H., Kranenburg, O., Xiao, H., & Yu, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0255-2 · Cited by 194
Use and application of 3D-organoid technology
Artegiani, B., & Clevers, H. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy187 · Cited by 193
An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity
Jiang, S., Zhao, H., Zhang, W., Wang, J., Liu, Y., Cao, Y., Zheng, H., Hu, Z., Wang, S., Zhu, Y., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100161 · Cited by 188
Narasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R. M., Vrbanac, L., Richardson, A. B., Kobayashi, H., Price, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0073 · Cited by 185
Xu, H., Jiao, Y., Qin, S., Zhao, W., Chu, Q., & Wu, K. (2018) · Experimental Hematology & Oncology · doi:10.1186/s40164-018-0122-9 · Cited by 186
The WNT signaling pathways in wound healing and fibrosis
Burgy, O., & Königshoff, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.017 · Cited by 175
Applications of organoids for cancer biology and precision medicine
Lo, Y.-H., Karlsson, K., & Kuo, C. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0102-y · Cited by 182
Metastatic disease in head & neck oncology
Pisani, P., Airoldi, M., Allais, A., Aluffi Valletti, P., Battista, M., Benazzo, M., Briatore, R., Cacciola, S., Cocuzza, S., Colombo, A., et al. (2020) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-suppl.1-40-2020 · Cited by 177
Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00359-0 · Cited by 178
Zhou, Z., Cong, L., & Cong, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762184 · Cited by 178
“applied patient-derived cancer organoids to predict the clinical outcomes of gastrointestinal cancer patients undergoing chemotherapy, targeted drug therapy and immunotherapy (64).”
BackgroundPatient-derived tumor organoids for prediction of cancer treatment response
Nagle, P. W., Plukker, J. T. M., Muijs, C. T., van Luijk, P., & Coppes, R. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.005 · Cited by 175
Booij, T. H., Price, L. S., & Danen, E. H. J. (2019) · SLAS Discovery · doi:10.1177/2472555219830087 · Cited by 176
“53 The tumor material can be genetically characterized and the observed therapeutic response can lead to highly personalized treatment suggestions.”
BackgroundTian, M., Wei, J., Lv, E., Li, C., Liu, G., Sun, Y., Yang, W., Wang, Q., Shen, C., Zhang, C., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155355 · Cited by 168
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications
Safri, F., Nguyen, R., Zerehpooshnesfchi, S., George, J., & Qiao, L. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00764-w · Cited by 162
“Over the past decades, organoids have been used to study tumor complexities, test drug ef fi cacy, and study the pathogenesis of tumor development [73 – 76].”
MethodMouse models of colorectal cancer: Past, present and future perspectives
Bürtin, F., Mullins, C. S., & Linnebacher, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i13.1394 · Cited by 170
Mapping the genomic diaspora of gastric cancer
Yeoh, K. G., & Tan, P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00412-7 · Cited by 169
Somatic cell-derived organoids as prototypes of human epithelial tissues and diseases
Fujii, M., & Sato, T. (2021) · Nature Materials · doi:10.1038/s41563-020-0754-0 · Cited by 165
Patient-derived xenografts and organoids model therapy response in prostate cancer
Karkampouna, S., La Manna, F., Benjak, A., Kiener, M., De Menna, M., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21300-6 · Cited by 161
Patient-derived organoids in precision cancer medicine
Tong, L., Cui, W., Zhang, B., Fonseca, P., Zhao, Q. C., Zhang, P., Xu, B., Zhang, Q., Li, Z., Seashore-Ludlow, B. A., et al. (2024) · Med · doi:10.1016/j.medj.2024.08.010 · Cited by 208
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer
Tran, T. Q., Hanse, E. A., Habowski, A. N., Li, H., Ishak Gabra, M. B., Yang, Y., Lowman, X. H., Ooi, A. M., Liao, S. Y., Edwards, R. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0035-5 · Cited by 161
Grassi, L., Alfonsi, R., Francescangeli, F., Signore, M., De Angelis, M. L., Addario, A., Costantini, M., Flex, E., Ciolfi, A., Pizzi, S., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1453-0 · Cited by 160
Organoid cultures for cancer modeling
Yan, H. H. N., Chan, A. S., Lai, F. P.-L., & Leung, S. Y. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.05.012 · Cited by 159
Yang, H., Cheng, J., Zhuang, H., Xu, H., Wang, Y., Zhang, T., Yang, Y., Qian, H.-G., Lu, Y., Han, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.004 · Cited by 187
Drug screening at single-organoid resolution via bioprinting and interferometry
Tebon, P. J., Wang, B., Markowitz, A. L., Davarifar, A., Krawczuk, P., Murray, G., Nguyen, H. T. L., Tavanaie, N., Nguyen, T. L., Boutros, P. C., et al. (2021) · doi:10.1101/2021.10.03.462896 · Cited by 155
Drug screening at single-organoid resolution via bioprinting and interferometry
Tebon, P. J., Wang, B., Markowitz, A. L., Davarifar, A., Tsai, B. L., Krawczuk, P., Gonzalez, A. E., Sartini, S., Murray, G. F., Nguyen, H. T. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38832-8 · Cited by 184
Zhang, C., Chen, L., Liu, Y., Huang, J., Liu, A., Xu, Y., Shen, Y., He, H., & Xu, D. (2021) · Theranostics · doi:10.7150/thno.55424 · Cited by 168
“original tumors and are useful preclinical models [28-30].”
BackgroundDecellularized Extracellular Matrix for Bioengineering Physiomimetic 3D in Vitro Tumor Models
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.04.006 · Cited by 153
Gocho, Y., Liu, J., Hu, J., Yang, W., Dharia, N. V., Zhang, J., Shi, H., Du, G., John, A., Lin, T.-N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00167-4 · Cited by 153
Sun, H., Wang, H., Wang, X., Aoki, Y., Wang, X., Yang, Y., Cheng, X., Wang, Z., & Wang, X. (2020) · Theranostics · doi:10.7150/thno.43811 · Cited by 169
“More recently, patient-derived organoids (PDO) representing tumor-relevant physiology and pathology have been successfully applied to achieve rapid assaying of phenotype– genotype correlations and drug sensitivity in many tumor types [8-10], offering an exceptional model to study cancer chemoresistance.”
BackgroundPromising Applications of Tumor Spheroids and Organoids for Personalized Medicine
Gilazieva, Z., Ponomarev, A., Rutland, C., Rizvanov, A., & Solovyeva, V. (2020) · Cancers · doi:10.3390/cancers12102727 · Cited by 151
“created a biobank of organoids from gastrointestinal tumors [132].”
BackgroundKim, S.-Y., Kim, S.-M., Lim, S., Lee, J. Y., Choi, S.-J., Yang, S.-D., Yun, M. R., Kim, C. G., Gu, S. R., Park, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5026 · Cited by 151
“Importantly, PDOs of colorectal cancer, head and neck cancer, gastrointestinal cancer, and rectal cancer have been shown to predict clinical responses to not only chemoradiotherapies but also targeted therapies, bringing new insight into the clinical utility of organoids (28, 29, 40, 41).”
BackgroundGut organoids: mini-tissues in culture to study intestinal physiology and disease
Almeqdadi, M., Mana, M. D., Roper, J., & Yilmaz, Ö. H. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00300.2017 · Cited by 148
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy
Álvarez-Varela, A., Novellasdemunt, L., Barriga, F. M., Hernando‐Momblona, X., Cañellas-Socias, A., Cano-Crespo, S., Sevillano, M., Cortina, C., Stork, D., Morral, C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00402-0 · Cited by 164
Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids
Mao, Y., Wang, W., Yang, J., Zhou, X., Lu, Y., Gao, J., Wang, X., Wen, L., Fu, W., & Tang, F. (2023) · Protein & Cell · doi:10.1093/procel/pwad038 · Cited by 161
“It has been widely reported that patient-derived orga-noids have been proved well predict the drug responses of cancer patients, indicating that the organoid model has great values for applications in drug discovery (Vlachogiannis et al., 2018; Yao et al., 2020).”
Patient-Derived Organoids for Precision Cancer Immunotherapy
Grönholm, M., Feodoroff, M., Antignani, G., Martins, B., Hamdan, F., & Cerullo, V. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4026 · Cited by 146
“Indeed, PDTOs have been used as preclinical models to predict response to anti-cancer agents (17)(18)(19).”
MethodPonsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 161
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
Ooft, S. N., Weeber, F., Schipper, L., Dijkstra, K. K., McLean, C. M., Kaing, S., van de Haar, J., Prevoo, W., van Werkhoven, E., Snaebjornsson, P., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100103 · Cited by 140
“As such, many groups are now pursuing organoid-based drug screening of patient tumor cells to guide clinical decision-making.(11,12,16) Here, we present the first formal, prospective intervention trial, the Selecting Cancer Patients for Treatment Using Tumor Organoids (SENSOR) trial, designed to evaluate the potential…”
BackgroundResultInfluentialOrganoids in gastrointestinal diseases: From experimental models to clinical translation
Günther, C., Winner, B., Neurath, M. F., & Stappenbeck, T. S. (2022) · Gut · doi:10.1136/gutjnl-2021-326560 · Cited by 145
“164 This allowed the authors to compare clinical responses of patients with organoid drug responses.”
BackgroundTowards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 165
“Drug sensitivity profiles in organoids have shown initial signs of consistency with patient response, with concordant results for several cytotoxic agents in gastrointestinal tumours 128,129 , and have been used to guide effective therapeutic decisions in a donor patient with TNBC 130 .”
Tanaka, N., Osman, A. A., Takahashi, Y., Lindemann, A., Patel, A. A., Zhao, M., Takahashi, H., & Myers, J. N. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.10.018 · Cited by 144
Transplantation of intestinal organoids into a mouse model of colitis
Watanabe, S., Kobayashi, S., Ogasawara, N., Okamoto, R., Nakamura, T., Watanabe, M., Jensen, K. B., & Yui, S. (2022) · Nature Protocols · doi:10.1038/s41596-021-00658-3 · Cited by 141
Applications of Human Brain Organoids to Clinical Problems
Chen, H. I., Song, H., & Ming, G. (2019) · Developmental Dynamics · doi:10.1002/dvdy.24662 · Cited by 141
Modeling Human Digestive Diseases With CRISPR-Cas9–Modified Organoids
Fujii, M., Clevers, H., & Sato, T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.048 · Cited by 140
Organoid based personalized medicine: from bench to bedside
Li, Y., Tang, P., Cai, S., Peng, J., & Hua, G. (2020) · Cell Regeneration · doi:10.1186/s13619-020-00059-z · Cited by 136
Patient-derived organoid (PDO) platforms to facilitate clinical decision making
Liu, L., Yu, L., Li, Z., Li, W., & Huang, W. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02677-2 · Cited by 159
“The study results showed 88% accuracy in predicting treatment response and 100% accuracy in predicting non-response to treatment [5].”
BackgroundMethodResultInfluentialPatient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment
Haque, M. R., Wessel, C. R., Leary, D. D., Wang, C., Bhushan, A., & Bishehsari, F. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00370-6 · Cited by 137
Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening
Li, Z., Qian, Y., Li, W., Liu, L., Yu, L., Liu, X., Wu, G., Wang, Y., Luo, W., Fang, F., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101411 · Cited by 137
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 181
Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids
Prince, E., Cruickshank, J., Ba-Alawi, W., Hodgson, K., Haight, J., Tobin, C., Wakeman, A., Avoulov, A., Topolskaia, V., Elliott, M. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28788-6 · Cited by 135
Tumor organoid models in precision medicine and investigating cancer-stromal interactions
Xu, R., Zhou, X., Wang, S., & Trinkle, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107668 · Cited by 134
Vessel co-option and resistance to anti-angiogenic therapy
Kuczynski, E. A., & Reynolds, A. R. (2019) · Angiogenesis · doi:10.1007/s10456-019-09698-6 · Cited by 148
Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling
Shukla, P., Yeleswarapu, S., Heinrich, M. A., Prakash, J., & Pati, F. (2022) · Biofabrication · doi:10.1088/1758-5090/ac6d11 · Cited by 148
“…drug testing and screening studies for multiple tumor types, for example, liver cancer [54–56], pancreatic cancer [57–59], brain cancer [60], prostate cancer, [61] stomach and colorectal cancer [62, 63], gastrointestinal cancer [64], bladder cancer [65], stomach cancer [66], and renal cancer [67].”
Cell-type-specific signaling networks in heterocellular organoids
Qin, X., Sufi, J., Vlckova, P., Kyriakidou, P., Acton, S. E., Li, V. S. W., Nitz, M., & Tape, C. J. (2020) · Nature Methods · doi:10.1038/s41592-020-0737-8 · Cited by 132
Decarli, M. C., do Amaral, R. L. F., dos Santos, D. P., Tofani, L. B., Katayama, E. T., Rezende, R. A., da Silva, J. V. L., Swiech, K., Suazo, C. A. T., Mota, C., et al. (2021) · Biofabrication · doi:10.1088/1758-5090/abe6f2 · Cited by 154
“Moreover, attempts to culture spheroids with primary tumor cells directly from patients (without expansion in mice) is a challenge that has made great progress in recent years [259].”
Harane, S. E., Zidi, B., Harane, N. E., Krause, K., Matthes, T., & Preynat‐Seauve, O. (2023) · Cells · doi:10.3390/cells12071001 · Cited by 154
“PDOs have been successfully generated from several cancer types such as breast cancer [33–36], lung cancer [37,38], gastro-intestinal cancer [39], gastroesophageal cancer [40], pancreatic cancer [41], ovarian cancer [42], prostate cancer [43], glioblastoma [44], liver cancer [45], colorectal cancer [46], retinoblastom…”
BackgroundOrganoids as host models for infection biology – a review of methods
Aguilar, C., da Silva, M. A., Saraiva, M., Neyazi, M., Olsson, I. A. S., & Bartfeld, S. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00629-4 · Cited by 138
Patient-Derived Cancer Organoids as Predictors of Treatment Response
Verduin, M., Hoeben, A., Ruysscher, D. D., & Vooijs, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641980 · Cited by 145
“However, only few studies have been able to make a quantitative clinical comparison to derive predictive values (11, 23, 25, 51).”
BackgroundDevelopment of a miniaturized 3D organoid culture platform for ultra-high-throughput screening
Du, Y., Li, X., Niu, Q., Mo, X., Qui, M., Ma, T., Kuo, C. J., & Fu, H. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa036 · Cited by 125
“Compared to the traditional 2D culture using transformed cell lines, primary organoids have the advantage of retaining the characteristics of the cancer cells from the original patient’s tissue, including their differentiated morphology and response to drugs (Clevers, 2016; Weeber et al., 2017; Abbasi, 2018; Sachs et…”
BackgroundApplications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Recent advances in organoid development and applications in disease modeling
Rauth, S., Karmakar, S., Batra, S. K., & Ponnusamy, M. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188527 · Cited by 149
“Vlachogiannis and the group have developed live organoid biobanks from patients with metastatic gastrointestinal cancer and compared the drug responses of the organoids with the patient response in the clinical trials [103].”
ResultOrganoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Grossman, J. E., Muthuswamy, L., Huang, L., Akshinthala, D., Perea, S., Gonzalez, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4116 · Cited by 121
“In addition, several studies have retrospectively tested the role of PDOs to predict response to conventional chemotherapy and have reported a high positive predictive value (22, 23).”
BackgroundResultSenkowski, W., Gall-Mas, L., Falco, M. M., Li, Y., Lavikka, K., Kriegbaum, M. C., Oikkonen, J., Bulanova, D. R., Pietras, E. J., Voßgröne, K., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.04.012 · Cited by 135
Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles
Yan, H. H. N., Siu, H. C., Ho, S. L., Yue, S. S. K., Gao, Y., Tsui, W. Y., Chan, D., Chan, A. S., Wong, J. W. H., Man, A. H. Y., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320019 · Cited by 121
“10 Given the fact that sporadic CRCs arising through the classical adenoma-carcinoma sequence, with mutational activation of the Wnt signalling pathway, constitutes ~80% of total CRC incidence, withdrawal of Wnt-3A and R-spondin1 in the culture medium can prevent normal organoid overgrowth, thereby…”
Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment
Madia, F., Worth, A. P., Whelan, M., & Corvi, R. (2019) · Environment International · doi:10.1016/j.envint.2019.04.067 · Cited by 139
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 150
Self-citationA flexible electronic strain sensor for the real-time monitoring of tumor regression
Abramson, A., Chan, C. T., Khan, Y., Mermin-Bunnell, A. M., Matsuhisa, N., Fong, R., Shad, R., Hiesinger, W., Mallick, P., Gambhir, S. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6550 · Cited by 128
High‐throughput screening in colorectal cancer tissue‐originated spheroids
Kondo, J., Ekawa, T., Endo, H., Yamazaki, K., Tanaka, N., Kukita, Y., Okuyama, H., Okami, J., Imamura, F., Ohue, M., et al. (2019) · Cancer Science · doi:10.1111/cas.13843 · Cited by 123
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Muir, A., Danai, L. V., & Vander Heiden, M. G. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035758 · Cited by 121
“In some cases, 3D culture models have been able to better predict tumor drug responses in vivo (Vlachogiannis et al., 2018; Lee et al., 2018); however, 3D cultures still lack the cell and matrix diversity”
BackgroundOrganoids are not organs: Sources of variation and misinformation in organoid biology
Jensen, K. B., & Little, M. H. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.05.009 · Cited by 139
Cancer research using organoid technology
Kretzschmar, K. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01990-z · Cited by 120
“CRC, gastro-oesophageal cancer, and cholangiocarcinoma) [87].”
BackgroundResultInfluentialFarin, H. F., Mosa, M. H., Ndreshkjana, B., Grebbin, B. M., Ritter, B., Menche, C., Kennel, K. B., Ziegler, P. K., Szabó, L., Bollrath, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0050 · Cited by 120
Li, W., Zhou, Z., Zhou, X., Khoo, B. L., Gunawan, R., Chin, Y. R., Zhang, L., Yi, C., Guan, X., & Yang, M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202609 · Cited by 119
Yang, Z., Xu, H., & Zhao, X. (2020) · Advanced Science · doi:10.1002/advs.201903718 · Cited by 128
Millen, R., de Kort, W. W. B., Koomen, M., van Son, G. J. F., Gobits, R., de Vries, B. B. L. P., Begthel, H., Zandvliet, M. M. J. M., Doornaert, P., Raaijmakers, C. P. J., et al. (2023) · Med · doi:10.1016/j.medj.2023.04.003 · Cited by 143
“10–13 To address whether organoids hold potential to stratify treatment for patients with head and neck cancer (HNC), we measured the response of organoids to either radiotherapy (RT) or chemoradiotherapy (CRT) and compared this with the response of patients diagnosed with primary HNC. HNC is a…”
Logun, M. T., Wang, X., Sun, Y. Y., Bagley, S. J., Li, N., Desai, A. S., Zhang, D. Y., Nasrallah, M. P., Pai, E. L.-L., Oner, B. S., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.010 · Cited by 144
Seppälä, T. T., Zimmerman, J. W., Sereni, E., Plenker, D., Suri, R., Rozich, N., Blair, A., Thomas, D. L., Teinor, J., Javed, A., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004200 · Cited by 117
3D and organoid culture in research: physiology, hereditary genetic diseases and cancer
Suarez-Martinez, E., Suazo-Sanchez, I., Celis-Romero, M., & Carnero, A. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00775-w · Cited by 118
The drug-induced phenotypic landscape of colorectal cancer organoids
Betge, J., Rindtorff, N., Sauer, J., Rauscher, B., Dingert, C., Gaitantzi, H., Herweck, F., Srour-Mhanna, K., Miersch, T., Valentini, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30722-9 · Cited by 112
Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment
Qu, Y., Dou, B., Tan, H., Feng, Y., Wang, N., & Wang, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0992-4 · Cited by 126
“In addition, recent studies have attempted to establish human organoids from biopsies to better understand cancer biology and further optimize cancer treatment [142, 143].”
BackgroundTrends in Droplet Microfluidics: From Droplet Generation to Biomedical Applications
Chen, Z., Kheiri, S., Young, E. W. K., & Kumacheva, E. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c00491 · Cited by 131
Strategies for 3D bioprinting of spheroids: A comprehensive review
Banerjee, D., Singh, Y. P., Datta, P., Özbolat, V., O'Donnell, A., Yeo, M., & Ozbolat, I. T. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121881 · Cited by 126
Functional precision oncology using patient-derived assays: bridging genotype and phenotype
van Renterghem, A. W. J., van de Haar, J., & Voest, E. E. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00745-2 · Cited by 131
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 113
Patient‐derived renal cell carcinoma organoids for personalized cancer therapy
Li, Z., Xu, H., Yu, L., Wang, J., Meng, Q., Mei, H., Cai, Z., Chen, W., & Huang, W. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.970 · Cited by 124
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Lawler, M., Davies, L., Oberst, S., Oliver, K. R., Eggermont, A. M. M., Schmutz, A., Vecchia, C. L., Allemani, C., Lievens, Y. N., Naredi, P. L. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00540-x · Cited by 130
Seidlitz, T., Chen, Y., Uhlemann, H., Schölch, S., Kochall, S., Merker, S. R., Klimová, A., Hennig, A., Schweitzer, C., Pape, K., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.026 · Cited by 120
From 2D to 3D Cancer Cell Models—The Enigmas of Drug Delivery Research
Van Zundert, I., Fortuni, B., & Rocha, S. (2020) · Nanomaterials · doi:10.3390/nano10112236 · Cited by 107
Seidlitz, T., Koo, B.-K., & Stange, D. E. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00662-2 · Cited by 108
Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments
Gómez‐Oliva, R., Domínguez‐García, S., Carrascal, L., Ábalos-Martínez, J., Pardillo-Díaz, R., Verástegui, C., Castro, C., Nunez‐Abades, P., & Geribaldi‐Doldán, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614295 · Cited by 120
Xiang, D., He, A., Zhou, R., Wang, Y., Xiao, X., Gong, T., Kang, W., Lin, X., Wang, X., Consortium11, P.-B. D., et al. (2024) · Theranostics · doi:10.7150/thno.96027 · Cited by 108
“Vlachogiannis reported in 2018 that organoid DST achieved a negative and positive predictive value of 100% and 88%, respectively, in advanced gastrointestinal cancer, paving the way for clinical application of PDO [38].”
BackgroundMethodInfluentialUbink, I., Bolhaqueiro, A. C. F., Elias, S. G., Raats, D., Constantinides, A., Peters, N. A., Wassenaar, E. C. E., de Hingh, I. H. J. T., Rovers, K. P. B., van Grevenstein, W. M. U., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11206 · Cited by 112
Cancer organoid co-culture model system: Novel approach to guide precision medicine
Yuan, J., Li, X., & Yu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061388 · Cited by 106
Bruun, J., Kryeziu, K., Eide, P. W., Moosavi, S. H., Eilertsen, I. A., Langerud, J., Røsok, B., Totland, M. Z., Brunsell, T. H., Pellinen, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3637 · Cited by 106
“The pharmacological landscape of PDOs from colorectal cancers has been investigated in a few studies (22, 25, 28), and there is evidence of intra-tumor heterogeneity in responses to selected drugs (29, 30).”
BackgroundMinoli, M., Cantore, T., Hanhart, D., Kiener, M., Fedrizzi, T., Manna, F. L., Karkampouna, S., Chouvardas, P., Genitsch, V., Rodríguez-Calero, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37696-2 · Cited by 127
“The concordance of the genomic profiles between PDO and PT has been already demonstrated in previous studies for BLCa (33,54) and upper urinary tract urothelial cancer (UTUC) (55) as well as for other cancer types such as breast (37), ovarian (31), rectal (40), gastrointestinal (39), pancreatic (38,56,57) and prostate…”
A pan-cancer organoid platform for precision medicine
Larsen, B. M., Kannan, M., Langer, L. F., Leibowitz, B. D., Bentaieb, A., Cancino, A., Dolgalev, I., Drummond, B. E., Dry, J. R., Ho, C.-S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109429 · Cited by 105
Ng, S., Tan, W. J., Pek, M. M. X., Tan, M.-H., & Kurisawa, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119400 · Cited by 105
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.